RM

Ronald Moss

Chief Executive Officer

DIOSynVax

Encinitas, California


Contact Information

Email
Unlock
LinkedIn

Company Information

Company
DIOSynVax
Industry
research
Employees
23.0
Seniority
C suite
Total Funding
2498629.0
Latest Funding
Other

Technologies

Outlook Google Font API Mobile Friendly WordPress.org Wix YouTube Apache Varnish

Keywords

biotechnology research vaccine antigen design vaccine antigen payload computational biology in vitro in vivo viruses pathogens pandemic preparedness vaccine vector nucleic acid-based dna vaccines mrna vaccines virus vectored vaccines protein-based custom vaccine design immune system broad protection deep protection viral mutations vaccine candidates synthetic antigens machine learning data reservoir epitope-rich regions adaptive immunity clinical trials biotechnology infectious diseases novel antigens immunology public health stability efficacy cross-family protection algorithm vaccine escape seasonal vaccine vaccine efficacy biopharmaceuticals novel vaccine development vaccine research epidemic response data-driven vaccine design profiling viral threats genetic sequence synthetic gene immune response vaccine innovation artificial intelligence information technology & services health care health wellness & fitness hospital & health care

Get Full Contact Details

Subscribe to reveal email addresses and export contacts.

View Plans